Clinical Trials Report for December 2014 | Aplastic Anemia and MDS International Foundation

Clinical Trials Report for December 2014

We have highlighted some clinical trials that were opened since the beginning of 2014. There are many others that are also underway. You can find them on ClinicalTrials.gov. Each trial has a specific purpose related to aplastic anemia, MDS, or PNH. Should you consider a clinical trial? Ask your doctor or contact the study coordinators for further information. Learn more in the Clinical Trials section.

To find out more about clinical trials at specific institutions near you, check their websites. Large academic healthcare institutions often identify the clinical trials being run by their researchers. Here is an example from MD Anderson.

Search for aplastic anemia studies actively recruiting patients. The following are a sample of the 67 studies that are actively recruiting aplastic anemia patients.

Title/Link to more information

Study Purpose

Study Coordinator

Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease Some treatments for cancer or other diseases can lead to infertility in women. These treatments include chemotherapy, some stem cell transplants, and pelvic radiotherapy. They are called gonadotoxic therapies. Women can now have their eggs frozen before they have these treatments. This may allow them to get pregnant later. Researchers want to learn more about this technology and processes.
This study if for women at least 18 years old who are past puberty and before menopause. They must be scheduled to have gonadotoxic therapies.
National Institutes of Health Clinical Center

Contact: Christine L Atallah, R.N.   
(301) 435-7926 christine.atallah@nih.gov
   
Please refer to this study by its ClinicalTrials.gov identifier: NCT02225145

Seach for myelodysplastic syndromes studies actively recruiting patients. The following MDS studies are a sample of the 288 open studies that are actively recruiting MDS patients.

Title/Link to more information

Study Purpose

Study Coordinator

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS. The safety of each study drug given on these schedules will also be studied. This study is being conducted at MD Anderson Cancer Center
Contact: Elias Jabbour, MD, 713-792-4764
Please refer to this study by its ClinicalTrials.gov identifier: NCT02269280




Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) The goal of this clinical research study is to compare how well two different schedules of giving busulfan with fludarabine and cladribine before a stem cell transplant in patients with AML or MDS may help to control the disease. The safety of this drug combination will also be studied. This study is being conducted at MD Anderson Cancer Center
Contact: Uday Popat, MD 713-792-8750
Please refer to this study by its ClinicalTrials.gov identifier: NCT02250937
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

This study is being performed to assess the safety, tolerability, and preliminary clinical effects of BVD-523 given orally, twice daily for 21-day cycles, in patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS). This study is being conducted at he University of Texas MD Anderson Cancer Center
Contact: Thomas Medina, RN, 713-745-1847 TEMedina@mdanderson.org 
Please refer to this study by its ClinicalTrials.gov identifier: NCT02296242

Search for a list of current paroxysmal nocturnal hemoglobinuria studies actively recruiting patients. The following are a sample of the 11 open studies for PNH patients in the United States.

Title/Link to more information

Study Purpose

Study Coordinator

Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

This study is a collection of data to evaluate safety and characterize progression of Paroxysmal Nocturnal Hemoglobinuria (PNH). Johns Hopkins University Medical Center , Baltimore
Contact: Lynn Sanders 203-439-9609 sandersl@alxn.com
Please refer to this study by its ClinicalTrials.gov identifier: NCT01374360